This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, J. H. Articles by Kim, B. K. Search for Related Content PubMed PubMed Citation Articles by Kim, J. H. Articles by Kim, B. K.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., Oct 1997, 2209-2213, Vol 41, No. 10
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone

JH Kim, JA Kang, YG Kim, JW Kim, JH Lee, EC Choi and BK Kim
Department of Microbial Chemistry, College of Pharmacy, Seoul National University, Korea.

CFC-222 is a novel fluoroquinolone containing a C-7 bicyclic amine moiety with potent antibacterial activities against gram-positive, gram- negative, and anaerobic organisms. We compared the in vitro and in vivo activities of CFC-222 with those of ciprofloxacin, ofloxacin, and lomefloxacin. CFC-222 was more active than the other fluoroquinolones tested against gram-positive bacteria. CFC-222 was particularly active against Streptococcus pneumoniae (MIC at which 90% of isolates are inhibited [MIC90], 0.2 microg/ml), Staphylococcus aureus (MIC90, 0.2 microg/ml for ciprofloxacin-susceptible strains), and Enterococcus faecalis (MIC90, 0.39 microg/ml). Against Escherichia coli and other members of the family Enterobacteriaceae, CFC-222 was slightly less active than ciprofloxacin (MIC90s for E. coli, 0.1 and 0.025 microg/ml, respectively). The in vitro activity of CFC-222 was not influenced by inoculum size, medium composition, or the presence of horse serum. However, its activity was decreased significantly by a change in the pH of the medium from 7.0 to 6.0, as was the case for the other quinolones tested. The in vivo protective efficacy of CFC-222 by oral administration was greater than those of the other quinolones tested in a mouse model of intraperitoneally inoculated systemic infection caused by S. aureus. CFC-222 exhibited efficacy comparable to that of ciprofloxacin in the same model of infection caused by gram-negative organisms, such as E. coli and Klebsiella pneumoniae. In this infection model, CFC-222 was slightly less active than ciprofloxacin against Pseudomonas aeruginosa. These results suggest that CFC-222 may be a promising therapeutic agent in various bacterial infections.

This article has been cited by other articles:

• Gentry-Weeks, C., Estay, M., Loui, C., Baker, D. (2003). Intravenous Mouse Infection Model for Studying the Pathology of Enterococcus faecalis Infections. Infect. Immun. 71: 1434-1441 [Abstract] [Full Text]  
• Yun, H.-J., Min, Y.-H., Lim, J.-A, Kang, J.-W., Kim, S.-Y., Kim, M.-J., Jeong, J.-H., Choi, Y.-J., Kwon, H.-J., Jung, Y.-H., Shim, M.-J., Choi, E.-C. (2002). In Vitro and In Vivo Antibacterial Activities of DW286, a New Fluoronaphthyridone Antibiotic. Antimicrob. Agents Chemother. 46: 3071-3074 [Abstract] [Full Text]